Ignite Creation Date:
2024-07-17 @ 10:42 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06488716
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-06-20
Brief Title:
A Study to Evaluate the Safety Pharmacokinetics and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase IaIb Open-Label Multicenter Study to Evaluate the Safety Pharmacokinetics and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human Phase IaIb open-label multicenter dose escalation and dose expansion study designed to evaluate the safety tolerability pharmacokinetics pharmacodynamics immunogenicity and preliminary anti-tumor activity of RO7759065 as a single agent Phase Ia or in combination with atezolizumab Phase Ib in patients with locally advanced recurrent or metastatic incurable solid tumor malignancies Several key aspects of the study design and study population are summarized below
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None